[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f5jIz6GsoESOu6C7QMC-5FOtQYiZ1OijGFj4x3lx0LZI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":41,"rows":48},"University Hospital, Bonn",[4],152,false,25,13,29030,1,110,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Healthy",7,{"name":18,"count":19},"Depression",6,{"name":21,"count":22},"Portal Hypertension",5,{"name":24,"count":25},"Cardiomyopathies",4,{"name":27,"count":25},"Heart Diseases",{"name":29,"count":30},"Pseudoxanthoma Elasticum",3,{"name":32,"count":30},"Major Depression",{"name":34,"count":30},"Healthy Male Volunteers",[36],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06810609","Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA\u002FB NSCLC","2029-12-31","Immunotherapy",[42,43,44,45,46,47],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[49,73,100,118,147,165,190,237,255,279,306,324,342,360,378,396,414,441,459,477,502,528,546,572,600,618,644,662,695,722,740,764,789,814,912,968,993,1011,1029,1047,1069,1094,1112,1130,1153,1178,1202,1227,1255,1280],{"intervention":40,"totalTrials":11,"cells":50},{"EARLY_PHASE1":51,"PHASE1":54,"PHASE2":56,"PHASE3":67,"PHASE4":69,"NA":71},{"trials":52,"activeCount":53},[],0,{"trials":55,"activeCount":53},[],{"trials":57,"activeCount":11,"soonestReadout":39},[58],{"nctId":37,"briefTitle":38,"status":59,"phases":60,"primaryCompletion":39,"completion":61,"start":62,"enrollment":63,"conditions":64,"interventions":66},"RECRUITING",[44],"2030-09-30","2025-04-20",176,[65],"Lung Cancer Non-Small Cell Cancer (NSCLC)",[40],{"trials":68,"activeCount":53},[],{"trials":70,"activeCount":53},[],{"trials":72,"activeCount":53},[],{"intervention":74,"totalTrials":11,"cells":75},"raltegravir",{"EARLY_PHASE1":76,"PHASE1":78,"PHASE2":80,"PHASE3":82,"PHASE4":84,"NA":98},{"trials":77,"activeCount":53},[],{"trials":79,"activeCount":53},[],{"trials":81,"activeCount":53},[],{"trials":83,"activeCount":53},[],{"trials":85,"activeCount":53},[86],{"nctId":87,"briefTitle":88,"status":89,"phases":90,"primaryCompletion":91,"completion":91,"start":92,"enrollment":53,"conditions":93,"interventions":96},"NCT01225705","Safety Study of Raltegravir in HIV\u002FHCV Co-infected Patients","WITHDRAWN",[46],"2012-08","2010-10",[94,95],"HIV","Hepatitis C",[74,97],"Atazanavir\u002Fritonavir",{"trials":99,"activeCount":53},[],{"intervention":97,"totalTrials":11,"cells":101},{"EARLY_PHASE1":102,"PHASE1":104,"PHASE2":106,"PHASE3":108,"PHASE4":110,"NA":116},{"trials":103,"activeCount":53},[],{"trials":105,"activeCount":53},[],{"trials":107,"activeCount":53},[],{"trials":109,"activeCount":53},[],{"trials":111,"activeCount":53},[112],{"nctId":87,"briefTitle":88,"status":89,"phases":113,"primaryCompletion":91,"completion":91,"start":92,"enrollment":53,"conditions":114,"interventions":115},[46],[94,95],[74,97],{"trials":117,"activeCount":53},[],{"intervention":119,"totalTrials":11,"cells":120},"Ketamine",{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":129,"NA":145},{"trials":122,"activeCount":53},[],{"trials":124,"activeCount":53},[],{"trials":126,"activeCount":53},[],{"trials":128,"activeCount":53},[],{"trials":130,"activeCount":53},[131],{"nctId":132,"briefTitle":133,"status":134,"phases":135,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":143},"NCT05320991","Effects of Ketamine on Mentalizing and Metacognition in Healthy Volunteers","COMPLETED",[46],"2020-09-27","2019-06-15",70,[140,141,142],"Ketamine-Induced Psychotic Disorder","Social Cognition","Theory of Mind",[119,144],"Nacl 0.9%",{"trials":146,"activeCount":53},[],{"intervention":144,"totalTrials":11,"cells":148},{"EARLY_PHASE1":149,"PHASE1":151,"PHASE2":153,"PHASE3":155,"PHASE4":157,"NA":163},{"trials":150,"activeCount":53},[],{"trials":152,"activeCount":53},[],{"trials":154,"activeCount":53},[],{"trials":156,"activeCount":53},[],{"trials":158,"activeCount":53},[159],{"nctId":132,"briefTitle":133,"status":134,"phases":160,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":161,"interventions":162},[46],[140,141,142],[119,144],{"trials":164,"activeCount":53},[],{"intervention":166,"totalTrials":11,"cells":167},"pegylated interferon",{"EARLY_PHASE1":168,"PHASE1":170,"PHASE2":172,"PHASE3":174,"PHASE4":176,"NA":188},{"trials":169,"activeCount":53},[],{"trials":171,"activeCount":53},[],{"trials":173,"activeCount":53},[],{"trials":175,"activeCount":53},[],{"trials":177,"activeCount":53},[178],{"nctId":179,"briefTitle":180,"status":134,"phases":181,"primaryCompletion":182,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":187},"NCT00132210","Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients",[46],"2010-06","2002-09",200,[95,186],"HIV Infections",[166],{"trials":189,"activeCount":53},[],{"intervention":191,"totalTrials":192,"cells":193},"Temozolomide",2,{"EARLY_PHASE1":194,"PHASE1":196,"PHASE2":198,"PHASE3":200,"PHASE4":233,"NA":235},{"trials":195,"activeCount":53},[],{"trials":197,"activeCount":53},[],{"trials":199,"activeCount":53},[],{"trials":201,"activeCount":53},[202,212],{"nctId":203,"briefTitle":204,"status":134,"phases":205,"primaryCompletion":206,"completion":206,"start":92,"enrollment":207,"conditions":208,"interventions":210},"NCT01149109","Efficacy and Safety Study of Lomustine\u002FTemozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients",[45],"2017-04-06",141,[209],"Glioblastoma",[211,191],"Temozolomide and lomustine",{"nctId":213,"briefTitle":214,"status":134,"phases":215,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":225},"NCT00749723","Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children",[44,45],"2015-01-31","2016-01-31","2006-02-01",174,[221,222,223,224],"Recurrent Brain Tumors","Supratentorial PNETs","Medulloblastomas","Ependymomas",[226,227,228,229,230,231,232],"carboplatin","etoposide","temozolomide","thiotepa, carboplatin, etoposide","temozolomide, thiotepa","intraventricular etoposide","trofosfamide, etoposide",{"trials":234,"activeCount":53},[],{"trials":236,"activeCount":53},[],{"intervention":211,"totalTrials":11,"cells":238},{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":251,"NA":253},{"trials":240,"activeCount":53},[],{"trials":242,"activeCount":53},[],{"trials":244,"activeCount":53},[],{"trials":246,"activeCount":53},[247],{"nctId":203,"briefTitle":204,"status":134,"phases":248,"primaryCompletion":206,"completion":206,"start":92,"enrollment":207,"conditions":249,"interventions":250},[45],[209],[211,191],{"trials":252,"activeCount":53},[],{"trials":254,"activeCount":53},[],{"intervention":256,"totalTrials":11,"cells":257},"Elontril",{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":264,"PHASE4":275,"NA":277},{"trials":259,"activeCount":53},[],{"trials":261,"activeCount":53},[],{"trials":263,"activeCount":53},[],{"trials":265,"activeCount":53},[266],{"nctId":267,"briefTitle":268,"status":134,"phases":269,"primaryCompletion":270,"completion":270,"start":271,"enrollment":12,"conditions":272,"interventions":274},"NCT01047254","Bupropion for the Treatment of Apathy in Alzheimer's Dementia",[45],"2014-07","2010-01",[273],"Apathy in Dementia",[256],{"trials":276,"activeCount":53},[],{"trials":278,"activeCount":53},[],{"intervention":280,"totalTrials":11,"cells":281},"Bromocriptin",{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":288,"PHASE4":302,"NA":304},{"trials":283,"activeCount":53},[],{"trials":285,"activeCount":53},[],{"trials":287,"activeCount":53},[],{"trials":289,"activeCount":53},[290],{"nctId":291,"briefTitle":292,"status":293,"phases":294,"completion":295,"start":296,"enrollment":297,"conditions":298,"interventions":301},"NCT00315081","Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine","UNKNOWN",[45],"2008-05","2006-05",20,[299,300],"Schizophrenia","Hyperprolactinemia",[280],{"trials":303,"activeCount":53},[],{"trials":305,"activeCount":53},[],{"intervention":226,"totalTrials":11,"cells":307},{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":314,"PHASE4":320,"NA":322},{"trials":309,"activeCount":53},[],{"trials":311,"activeCount":53},[],{"trials":313,"activeCount":53},[],{"trials":315,"activeCount":53},[316],{"nctId":213,"briefTitle":214,"status":134,"phases":317,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":318,"interventions":319},[44,45],[221,222,223,224],[226,227,228,229,230,231,232],{"trials":321,"activeCount":53},[],{"trials":323,"activeCount":53},[],{"intervention":227,"totalTrials":11,"cells":325},{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":338,"NA":340},{"trials":327,"activeCount":53},[],{"trials":329,"activeCount":53},[],{"trials":331,"activeCount":53},[],{"trials":333,"activeCount":53},[334],{"nctId":213,"briefTitle":214,"status":134,"phases":335,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":336,"interventions":337},[44,45],[221,222,223,224],[226,227,228,229,230,231,232],{"trials":339,"activeCount":53},[],{"trials":341,"activeCount":53},[],{"intervention":229,"totalTrials":11,"cells":343},{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":350,"PHASE4":356,"NA":358},{"trials":345,"activeCount":53},[],{"trials":347,"activeCount":53},[],{"trials":349,"activeCount":53},[],{"trials":351,"activeCount":53},[352],{"nctId":213,"briefTitle":214,"status":134,"phases":353,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":354,"interventions":355},[44,45],[221,222,223,224],[226,227,228,229,230,231,232],{"trials":357,"activeCount":53},[],{"trials":359,"activeCount":53},[],{"intervention":230,"totalTrials":11,"cells":361},{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":366,"PHASE3":368,"PHASE4":374,"NA":376},{"trials":363,"activeCount":53},[],{"trials":365,"activeCount":53},[],{"trials":367,"activeCount":53},[],{"trials":369,"activeCount":53},[370],{"nctId":213,"briefTitle":214,"status":134,"phases":371,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":372,"interventions":373},[44,45],[221,222,223,224],[226,227,228,229,230,231,232],{"trials":375,"activeCount":53},[],{"trials":377,"activeCount":53},[],{"intervention":231,"totalTrials":11,"cells":379},{"EARLY_PHASE1":380,"PHASE1":382,"PHASE2":384,"PHASE3":386,"PHASE4":392,"NA":394},{"trials":381,"activeCount":53},[],{"trials":383,"activeCount":53},[],{"trials":385,"activeCount":53},[],{"trials":387,"activeCount":53},[388],{"nctId":213,"briefTitle":214,"status":134,"phases":389,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":390,"interventions":391},[44,45],[221,222,223,224],[226,227,228,229,230,231,232],{"trials":393,"activeCount":53},[],{"trials":395,"activeCount":53},[],{"intervention":232,"totalTrials":11,"cells":397},{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":404,"PHASE4":410,"NA":412},{"trials":399,"activeCount":53},[],{"trials":401,"activeCount":53},[],{"trials":403,"activeCount":53},[],{"trials":405,"activeCount":53},[406],{"nctId":213,"briefTitle":214,"status":134,"phases":407,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":408,"interventions":409},[44,45],[221,222,223,224],[226,227,228,229,230,231,232],{"trials":411,"activeCount":53},[],{"trials":413,"activeCount":53},[],{"intervention":415,"totalTrials":11,"cells":416},"pegylated interferon alfa-2a",{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":423,"PHASE4":437,"NA":439},{"trials":418,"activeCount":53},[],{"trials":420,"activeCount":53},[],{"trials":422,"activeCount":53},[],{"trials":424,"activeCount":53},[425],{"nctId":426,"briefTitle":427,"status":428,"phases":429,"primaryCompletion":430,"completion":430,"start":431,"enrollment":192,"conditions":432,"interventions":434},"NCT00221286","Efficacy and Safety of PegIFN +\u002F- FTC \u002F TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients","TERMINATED",[45],"2007-01","2004-09",[433,186],"Chronic Hepatitis B",[415,435,436],"tenofovir DF \u002F emtricitabine combination therapy","pegIFN \u002F TDF \u002F FTC combination therapy",{"trials":438,"activeCount":53},[],{"trials":440,"activeCount":53},[],{"intervention":435,"totalTrials":11,"cells":442},{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":447,"PHASE3":449,"PHASE4":455,"NA":457},{"trials":444,"activeCount":53},[],{"trials":446,"activeCount":53},[],{"trials":448,"activeCount":53},[],{"trials":450,"activeCount":53},[451],{"nctId":426,"briefTitle":427,"status":428,"phases":452,"primaryCompletion":430,"completion":430,"start":431,"enrollment":192,"conditions":453,"interventions":454},[45],[433,186],[415,435,436],{"trials":456,"activeCount":53},[],{"trials":458,"activeCount":53},[],{"intervention":436,"totalTrials":11,"cells":460},{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":467,"PHASE4":473,"NA":475},{"trials":462,"activeCount":53},[],{"trials":464,"activeCount":53},[],{"trials":466,"activeCount":53},[],{"trials":468,"activeCount":53},[469],{"nctId":426,"briefTitle":427,"status":428,"phases":470,"primaryCompletion":430,"completion":430,"start":431,"enrollment":192,"conditions":471,"interventions":472},[45],[433,186],[415,435,436],{"trials":474,"activeCount":53},[],{"trials":476,"activeCount":53},[],{"intervention":478,"totalTrials":11,"cells":479},"N-Acetylcysteine",{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":498,"NA":500},{"trials":481,"activeCount":53},[],{"trials":483,"activeCount":53},[],{"trials":485,"activeCount":53},[],{"trials":487,"activeCount":53},[488],{"nctId":489,"briefTitle":490,"status":428,"phases":491,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":497},"NCT03149107","\"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients\"",[45],"2021-01","2016-09-01",48,[496],"Prodromal Schizophrenia",[478],{"trials":499,"activeCount":53},[],{"trials":501,"activeCount":53},[],{"intervention":503,"totalTrials":11,"cells":504},"Tacrolimus",{"EARLY_PHASE1":505,"PHASE1":507,"PHASE2":509,"PHASE3":511,"PHASE4":524,"NA":526},{"trials":506,"activeCount":53},[],{"trials":508,"activeCount":53},[],{"trials":510,"activeCount":53},[],{"trials":512,"activeCount":53},[513],{"nctId":514,"briefTitle":515,"status":293,"phases":516,"primaryCompletion":517,"completion":517,"start":518,"enrollment":519,"conditions":520,"interventions":522},"NCT00545493","Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen Encephalitis",[44,45],"2010-04","2002-11",16,[521],"Rasmussen Encephalitis",[503,523],"i.v. immunoglobulins",{"trials":525,"activeCount":53},[],{"trials":527,"activeCount":53},[],{"intervention":523,"totalTrials":11,"cells":529},{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":542,"NA":544},{"trials":531,"activeCount":53},[],{"trials":533,"activeCount":53},[],{"trials":535,"activeCount":53},[],{"trials":537,"activeCount":53},[538],{"nctId":514,"briefTitle":515,"status":293,"phases":539,"primaryCompletion":517,"completion":517,"start":518,"enrollment":519,"conditions":540,"interventions":541},[44,45],[521],[503,523],{"trials":543,"activeCount":53},[],{"trials":545,"activeCount":53},[],{"intervention":547,"totalTrials":11,"cells":548},"Dexamethasone",{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":555,"PHASE4":568,"NA":570},{"trials":550,"activeCount":53},[],{"trials":552,"activeCount":53},[],{"trials":554,"activeCount":53},[],{"trials":556,"activeCount":53},[557],{"nctId":558,"briefTitle":559,"status":293,"phases":560,"primaryCompletion":561,"completion":562,"start":563,"enrollment":564,"conditions":565,"interventions":567},"NCT05132920","Fight INflammation to Improve Outcome After Aneurysmal Subarachnoid HEmorRhage",[45],"2024-12","2025-12","2021-12-03",334,[566],"Aneurysmal Subarachnoid Hemorrhage",[547],{"trials":569,"activeCount":53},[],{"trials":571,"activeCount":53},[],{"intervention":573,"totalTrials":11,"cells":574},"Pravastatin",{"EARLY_PHASE1":575,"PHASE1":577,"PHASE2":579,"PHASE3":581,"PHASE4":596,"NA":598},{"trials":576,"activeCount":53},[],{"trials":578,"activeCount":53},[],{"trials":580,"activeCount":53},[],{"trials":582,"activeCount":53},[583],{"nctId":584,"briefTitle":585,"status":134,"phases":586,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":591,"interventions":594},"NCT01057654","A Study Comparing the Mechanisms of Action of Lifibrol and Pravastatin",[45],"1996-04","1998-06","1996-01",18,[592,593],"Hypercholesterolemia","Hyperlipoproteinemia",[573,595],"Lifibrol",{"trials":597,"activeCount":53},[],{"trials":599,"activeCount":53},[],{"intervention":595,"totalTrials":11,"cells":601},{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":608,"PHASE4":614,"NA":616},{"trials":603,"activeCount":53},[],{"trials":605,"activeCount":53},[],{"trials":607,"activeCount":53},[],{"trials":609,"activeCount":53},[610],{"nctId":584,"briefTitle":585,"status":134,"phases":611,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":612,"interventions":613},[45],[592,593],[573,595],{"trials":615,"activeCount":53},[],{"trials":617,"activeCount":53},[],{"intervention":619,"totalTrials":11,"cells":620},"Phenprocoumon",{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":627,"PHASE4":640,"NA":642},{"trials":622,"activeCount":53},[],{"trials":624,"activeCount":53},[],{"trials":626,"activeCount":53},[],{"trials":628,"activeCount":53},[629],{"nctId":630,"briefTitle":631,"status":293,"phases":632,"primaryCompletion":633,"completion":633,"start":634,"enrollment":635,"conditions":636,"interventions":638},"NCT00895505","D-Dimer Guided Oral Anticoagulant Treatment (OAT)",[45],"2012-02","2008-02",300,[637],"Deep Venous Thrombosis",[619,639],"Warfarin-Natrium",{"trials":641,"activeCount":53},[],{"trials":643,"activeCount":53},[],{"intervention":639,"totalTrials":11,"cells":645},{"EARLY_PHASE1":646,"PHASE1":648,"PHASE2":650,"PHASE3":652,"PHASE4":658,"NA":660},{"trials":647,"activeCount":53},[],{"trials":649,"activeCount":53},[],{"trials":651,"activeCount":53},[],{"trials":653,"activeCount":53},[654],{"nctId":630,"briefTitle":631,"status":293,"phases":655,"primaryCompletion":633,"completion":633,"start":634,"enrollment":635,"conditions":656,"interventions":657},[45],[637],[619,639],{"trials":659,"activeCount":53},[],{"trials":661,"activeCount":53},[],{"intervention":663,"totalTrials":192,"cells":664},"Intravitreal injection ranibizumab",{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":689,"PHASE4":691,"NA":693},{"trials":666,"activeCount":53},[],{"trials":668,"activeCount":53},[],{"trials":670,"activeCount":53},[671,682],{"nctId":672,"briefTitle":673,"status":134,"phases":674,"primaryCompletion":675,"completion":676,"start":677,"enrollment":678,"conditions":679,"interventions":681},"NCT00504400","Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)",[44],"2009-06","2009-09","2007-08",10,[680],"Type 2 Idiopathic Macular Telangiectasia",[663],{"nctId":683,"briefTitle":684,"status":134,"phases":685,"primaryCompletion":517,"completion":517,"start":677,"enrollment":678,"conditions":686,"interventions":688},"NCT00510965","Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)",[44],[687],"Choroidal Neovascularization",[663],{"trials":690,"activeCount":53},[],{"trials":692,"activeCount":53},[],{"trials":694,"activeCount":53},[],{"intervention":696,"totalTrials":11,"cells":697},"thalidomide",{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":716,"PHASE4":718,"NA":720},{"trials":699,"activeCount":53},[],{"trials":701,"activeCount":53},[],{"trials":703,"activeCount":53},[704],{"nctId":705,"briefTitle":706,"status":293,"phases":707,"primaryCompletion":708,"completion":709,"start":710,"enrollment":711,"conditions":712,"interventions":714},"NCT00124813","Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma",[44],"2010-05","2010-11","2002-08",80,[713],"Multiple Myeloma",[696,715],"idarubicin",{"trials":717,"activeCount":53},[],{"trials":719,"activeCount":53},[],{"trials":721,"activeCount":53},[],{"intervention":715,"totalTrials":11,"cells":723},{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":728,"PHASE3":734,"PHASE4":736,"NA":738},{"trials":725,"activeCount":53},[],{"trials":727,"activeCount":53},[],{"trials":729,"activeCount":53},[730],{"nctId":705,"briefTitle":706,"status":293,"phases":731,"primaryCompletion":708,"completion":709,"start":710,"enrollment":711,"conditions":732,"interventions":733},[44],[713],[696,715],{"trials":735,"activeCount":53},[],{"trials":737,"activeCount":53},[],{"trials":739,"activeCount":53},[],{"intervention":741,"totalTrials":11,"cells":742},"Aflibercept",{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":758,"PHASE4":760,"NA":762},{"trials":744,"activeCount":53},[],{"trials":746,"activeCount":53},[],{"trials":748,"activeCount":53},[749],{"nctId":750,"briefTitle":751,"status":134,"phases":752,"primaryCompletion":753,"completion":753,"start":754,"enrollment":755,"conditions":756,"interventions":757},"NCT02537054","Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)",[44],"2018-07-02","2015-09",15,[29],[741],{"trials":759,"activeCount":53},[],{"trials":761,"activeCount":53},[],{"trials":763,"activeCount":53},[],{"intervention":765,"totalTrials":11,"cells":766},"cladribine",{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":771,"PHASE3":783,"PHASE4":785,"NA":787},{"trials":768,"activeCount":53},[],{"trials":770,"activeCount":53},[],{"trials":772,"activeCount":53},[773],{"nctId":774,"briefTitle":775,"status":293,"phases":776,"primaryCompletion":709,"completion":777,"start":778,"enrollment":779,"conditions":780,"interventions":782},"NCT00126321","Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)",[44],"2011-03","2004-11",50,[781],"Leukemia, Myelocytic, Acute",[765],{"trials":784,"activeCount":53},[],{"trials":786,"activeCount":53},[],{"trials":788,"activeCount":53},[],{"intervention":790,"totalTrials":11,"cells":791},"Ranibizumab",{"EARLY_PHASE1":792,"PHASE1":794,"PHASE2":796,"PHASE3":808,"PHASE4":810,"NA":812},{"trials":793,"activeCount":53},[],{"trials":795,"activeCount":53},[],{"trials":797,"activeCount":53},[798],{"nctId":799,"briefTitle":800,"status":134,"phases":801,"primaryCompletion":802,"completion":802,"start":803,"enrollment":804,"conditions":805,"interventions":807},"NCT01914159","Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study",[44],"2016-03","2013-02",24,[806],"Age Related Macular Degeneration",[790],{"trials":809,"activeCount":53},[],{"trials":811,"activeCount":53},[],{"trials":813,"activeCount":53},[],{"intervention":815,"totalTrials":816,"cells":817},"Oxytocin",9,{"EARLY_PHASE1":818,"PHASE1":828,"PHASE2":904,"PHASE3":906,"PHASE4":908,"NA":910},{"trials":819,"activeCount":53},[820],{"nctId":821,"briefTitle":822,"status":134,"phases":823,"primaryCompletion":824,"completion":824,"start":91,"enrollment":825,"conditions":826,"interventions":827},"NCT01701180","Neural Correlates of Empathogenic and Affiliative Actions of Oxytocin",[42],"2013-08",23,[15],[815],{"trials":829,"activeCount":53},[830,839,849,859,867,877,888,896],{"nctId":831,"briefTitle":832,"status":134,"phases":833,"primaryCompletion":834,"completion":834,"start":835,"enrollment":836,"conditions":837,"interventions":838},"NCT01606462","Oxytocin and Social Cognition",[43],"2013-06","2011-06",153,[34],[815],{"nctId":840,"briefTitle":841,"status":134,"phases":842,"primaryCompletion":843,"completion":843,"start":844,"enrollment":845,"conditions":846,"interventions":848},"NCT02156661","Oxytocin and Emotion Processing",[43],"2014-06","2013-05",97,[847],"Healthy Males",[815],{"nctId":850,"briefTitle":851,"status":134,"phases":852,"primaryCompletion":853,"completion":854,"start":855,"enrollment":856,"conditions":857,"interventions":858},"NCT03011970","Temporal Dynamics and Pharmacokinetics of Intranasally Administered Oxytocin",[43],"2015-12","2016-02","2014-09",116,[15],[815],{"nctId":860,"briefTitle":861,"status":134,"phases":862,"primaryCompletion":834,"completion":824,"start":863,"enrollment":864,"conditions":865,"interventions":866},"NCT01939639","The Influence of Oxytocin on the Processing of Social Contact",[43],"2013-03",40,[34],[815],{"nctId":868,"briefTitle":869,"status":134,"phases":870,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":874,"interventions":876},"NCT03265899","Oxytocin and the Processing of Social Stress-Associated Chemosignals",[43],"2016-11-30","2015-07-01",60,[875],"Healthy Volunteers",[815],{"nctId":878,"briefTitle":879,"status":134,"phases":880,"primaryCompletion":881,"completion":881,"start":882,"enrollment":883,"conditions":884,"interventions":886},"NCT03829839","Effects of Oxytocin and Lorazepam on Fear-related Intra-amygdalar Activity",[43],"2017-08-16","2016-03-03",120,[885],"Oxytocin, Lorazepam, Anti-Anxiety Agents, Physiological Effects of Drugs",[815,887],"Lorazepam 1 mg",{"nctId":889,"briefTitle":890,"status":134,"phases":891,"primaryCompletion":892,"completion":892,"start":893,"enrollment":711,"conditions":894,"interventions":895},"NCT01607970","Oxytocin Modulation of Startle Reactivity to Social Stimuli and Moral Decision Making",[43],"2012-05","2011-08",[34],[815],{"nctId":897,"briefTitle":898,"status":134,"phases":899,"primaryCompletion":900,"completion":900,"start":901,"enrollment":138,"conditions":902,"interventions":903},"NCT03425929","Oxytocin, Trauma Disclosure and Intrusions",[43],"2017-03-18","2016-06-01",[15],[815],{"trials":905,"activeCount":53},[],{"trials":907,"activeCount":53},[],{"trials":909,"activeCount":53},[],{"trials":911,"activeCount":53},[],{"intervention":913,"totalTrials":25,"cells":914},"Oxytocin nasal spray",{"EARLY_PHASE1":915,"PHASE1":917,"PHASE2":960,"PHASE3":962,"PHASE4":964,"NA":966},{"trials":916,"activeCount":53},[],{"trials":918,"activeCount":53},[919,928,942,950],{"nctId":920,"briefTitle":921,"status":134,"phases":922,"primaryCompletion":923,"completion":923,"start":924,"enrollment":925,"conditions":926,"interventions":927},"NCT03846739","Dose-dependent Effects of Oxytocin on the Amygdala and Reward System",[43],"2018-12-31","2017-04-03",92,[15],[913],{"nctId":929,"briefTitle":930,"status":134,"phases":931,"primaryCompletion":932,"completion":932,"start":933,"enrollment":934,"conditions":935,"interventions":940},"NCT04330677","Dissecting the Role of Estradiol in Mediating Gender-specific Anxiolytic and Prosocial Effects of Oxytocin",[43],"2020-01-25","2016-09-18",487,[815,936,937,938,939],"Estrogen","Fear Extinction","Emotion Processing","Memory",[913,941],"Estrogen Gel",{"nctId":943,"briefTitle":944,"status":293,"phases":945,"primaryCompletion":946,"completion":946,"start":947,"enrollment":873,"conditions":948,"interventions":949},"NCT04292444","Effects of Oxytocin on Cognitive and Reactive Fear",[43],"2021-05","2019-12-13",[815],[913],{"nctId":951,"briefTitle":952,"status":293,"phases":953,"primaryCompletion":954,"completion":955,"start":956,"enrollment":873,"conditions":957,"interventions":959},"NCT04137432","Oxytocin-augmented Cognitive-behavioral Group-based Short-term Intervention for Loneliness",[43],"2020-09","2020-12","2019-09-26",[958],"Loneliness",[913],{"trials":961,"activeCount":53},[],{"trials":963,"activeCount":53},[],{"trials":965,"activeCount":53},[],{"trials":967,"activeCount":53},[],{"intervention":969,"totalTrials":11,"cells":970},"Lomustine",{"EARLY_PHASE1":971,"PHASE1":973,"PHASE2":985,"PHASE3":987,"PHASE4":989,"NA":991},{"trials":972,"activeCount":53},[],{"trials":974,"activeCount":53},[975],{"nctId":976,"briefTitle":977,"status":428,"phases":978,"primaryCompletion":979,"completion":979,"start":980,"enrollment":11,"conditions":981,"interventions":983},"NCT01563614","A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain",[43],"2015-11","2012-03",[982],"Leptomeningeal Metastasis From Malignant Melanoma",[969,984],"Liposomal cytarabine",{"trials":986,"activeCount":53},[],{"trials":988,"activeCount":53},[],{"trials":990,"activeCount":53},[],{"trials":992,"activeCount":53},[],{"intervention":984,"totalTrials":11,"cells":994},{"EARLY_PHASE1":995,"PHASE1":997,"PHASE2":1003,"PHASE3":1005,"PHASE4":1007,"NA":1009},{"trials":996,"activeCount":53},[],{"trials":998,"activeCount":53},[999],{"nctId":976,"briefTitle":977,"status":428,"phases":1000,"primaryCompletion":979,"completion":979,"start":980,"enrollment":11,"conditions":1001,"interventions":1002},[43],[982],[969,984],{"trials":1004,"activeCount":53},[],{"trials":1006,"activeCount":53},[],{"trials":1008,"activeCount":53},[],{"trials":1010,"activeCount":53},[],{"intervention":941,"totalTrials":11,"cells":1012},{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1021,"PHASE3":1023,"PHASE4":1025,"NA":1027},{"trials":1014,"activeCount":53},[],{"trials":1016,"activeCount":53},[1017],{"nctId":929,"briefTitle":930,"status":134,"phases":1018,"primaryCompletion":932,"completion":932,"start":933,"enrollment":934,"conditions":1019,"interventions":1020},[43],[815,936,937,938,939],[913,941],{"trials":1022,"activeCount":53},[],{"trials":1024,"activeCount":53},[],{"trials":1026,"activeCount":53},[],{"trials":1028,"activeCount":53},[],{"intervention":887,"totalTrials":11,"cells":1030},{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1039,"PHASE3":1041,"PHASE4":1043,"NA":1045},{"trials":1032,"activeCount":53},[],{"trials":1034,"activeCount":53},[1035],{"nctId":878,"briefTitle":879,"status":134,"phases":1036,"primaryCompletion":881,"completion":881,"start":882,"enrollment":883,"conditions":1037,"interventions":1038},[43],[885],[815,887],{"trials":1040,"activeCount":53},[],{"trials":1042,"activeCount":53},[],{"trials":1044,"activeCount":53},[],{"trials":1046,"activeCount":53},[],{"intervention":1048,"totalTrials":11,"cells":1049},"Syntocinon-Spray",{"EARLY_PHASE1":1050,"PHASE1":1059,"PHASE2":1061,"PHASE3":1063,"PHASE4":1065,"NA":1067},{"trials":1051,"activeCount":53},[1052],{"nctId":1053,"briefTitle":1054,"status":134,"phases":1055,"primaryCompletion":1056,"completion":1056,"start":270,"enrollment":864,"conditions":1057,"interventions":1058},"NCT02501837","The Influence of Oxytocin on Pair-bonding and Emotion Regulation",[42],"2015-06",[15],[1048],{"trials":1060,"activeCount":53},[],{"trials":1062,"activeCount":53},[],{"trials":1064,"activeCount":53},[],{"trials":1066,"activeCount":53},[],{"trials":1068,"activeCount":53},[],{"intervention":1070,"totalTrials":11,"cells":1071},"Sugar pill",{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1078,"PHASE4":1080,"NA":1082},{"trials":1073,"activeCount":53},[],{"trials":1075,"activeCount":53},[],{"trials":1077,"activeCount":53},[],{"trials":1079,"activeCount":53},[],{"trials":1081,"activeCount":53},[],{"trials":1083,"activeCount":53},[1084],{"nctId":1085,"briefTitle":1086,"status":134,"phases":1087,"primaryCompletion":893,"completion":893,"start":1088,"enrollment":883,"conditions":1089,"interventions":1091},"NCT00980408","The Influence of Glutamate on Memory in Humans",[47],"2008-06",[1090],"Healthy Individuals",[1070,1070,1070,1070,1092,1092,1093,1093],"Glutamic Acid","Memantine",{"intervention":1092,"totalTrials":11,"cells":1095},{"EARLY_PHASE1":1096,"PHASE1":1098,"PHASE2":1100,"PHASE3":1102,"PHASE4":1104,"NA":1106},{"trials":1097,"activeCount":53},[],{"trials":1099,"activeCount":53},[],{"trials":1101,"activeCount":53},[],{"trials":1103,"activeCount":53},[],{"trials":1105,"activeCount":53},[],{"trials":1107,"activeCount":53},[1108],{"nctId":1085,"briefTitle":1086,"status":134,"phases":1109,"primaryCompletion":893,"completion":893,"start":1088,"enrollment":883,"conditions":1110,"interventions":1111},[47],[1090],[1070,1070,1070,1070,1092,1092,1093,1093],{"intervention":1093,"totalTrials":11,"cells":1113},{"EARLY_PHASE1":1114,"PHASE1":1116,"PHASE2":1118,"PHASE3":1120,"PHASE4":1122,"NA":1124},{"trials":1115,"activeCount":53},[],{"trials":1117,"activeCount":53},[],{"trials":1119,"activeCount":53},[],{"trials":1121,"activeCount":53},[],{"trials":1123,"activeCount":53},[],{"trials":1125,"activeCount":53},[1126],{"nctId":1085,"briefTitle":1086,"status":134,"phases":1127,"primaryCompletion":893,"completion":893,"start":1088,"enrollment":883,"conditions":1128,"interventions":1129},[47],[1090],[1070,1070,1070,1070,1092,1092,1093,1093],{"intervention":1131,"totalTrials":11,"cells":1132},"Transdermal nicotine patch",{"EARLY_PHASE1":1133,"PHASE1":1135,"PHASE2":1137,"PHASE3":1139,"PHASE4":1141,"NA":1143},{"trials":1134,"activeCount":53},[],{"trials":1136,"activeCount":53},[],{"trials":1138,"activeCount":53},[],{"trials":1140,"activeCount":53},[],{"trials":1142,"activeCount":53},[],{"trials":1144,"activeCount":53},[1145],{"nctId":1146,"briefTitle":1147,"status":134,"phases":1148,"primaryCompletion":980,"completion":980,"start":1149,"enrollment":1150,"conditions":1151,"interventions":1152},"NCT01315002","Nicotine Effects on Endophenotypes of Schizophrenia",[47],"2008-07",121,[299],[1131],{"intervention":1154,"totalTrials":11,"cells":1155},"simvastatin",{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1160,"PHASE3":1162,"PHASE4":1164,"NA":1166},{"trials":1157,"activeCount":53},[],{"trials":1159,"activeCount":53},[],{"trials":1161,"activeCount":53},[],{"trials":1163,"activeCount":53},[],{"trials":1165,"activeCount":53},[],{"trials":1167,"activeCount":53},[1168],{"nctId":1169,"briefTitle":1170,"status":134,"phases":1171,"primaryCompletion":1172,"completion":1173,"start":1174,"enrollment":1175,"conditions":1176,"interventions":1177},"NCT00905541","Influence of Simvastatin on Apolipoprotein B-100 (apoB-100) Secretion",[47],"1999-03","2000-03","1998-11",8,[592],[1154,1154],{"intervention":1179,"totalTrials":11,"cells":1180},"Reminyl retard",{"EARLY_PHASE1":1181,"PHASE1":1183,"PHASE2":1185,"PHASE3":1187,"PHASE4":1189,"NA":1191},{"trials":1182,"activeCount":53},[],{"trials":1184,"activeCount":53},[],{"trials":1186,"activeCount":53},[],{"trials":1188,"activeCount":53},[],{"trials":1190,"activeCount":53},[],{"trials":1192,"activeCount":53},[1193],{"nctId":1194,"briefTitle":1195,"status":293,"phases":1196,"primaryCompletion":1197,"start":634,"enrollment":1198,"conditions":1199,"interventions":1201},"NCT00637442","Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)",[47],"2010-12",30,[1200],"Alzheimer's Disease",[1179],{"intervention":1203,"totalTrials":11,"cells":1204},"TB treatment according to national guidelines",{"EARLY_PHASE1":1205,"PHASE1":1207,"PHASE2":1209,"PHASE3":1211,"PHASE4":1213,"NA":1215},{"trials":1206,"activeCount":53},[],{"trials":1208,"activeCount":53},[],{"trials":1210,"activeCount":53},[],{"trials":1212,"activeCount":53},[],{"trials":1214,"activeCount":53},[],{"trials":1216,"activeCount":53},[1217],{"nctId":1218,"briefTitle":1219,"status":293,"phases":1220,"primaryCompletion":1221,"completion":1221,"start":1222,"enrollment":1223,"conditions":1224,"interventions":1226},"NCT04547738","Influence of Filarial Infections on Tuberculosis Disease and Tuberculosis Vaccination in Cameroon",[],"2023-10-01","2020-12-01",2500,[1225],"Tuberculosis",[1203],{"intervention":1228,"totalTrials":11,"cells":1229},"Medication - Treatment as usual",{"EARLY_PHASE1":1230,"PHASE1":1232,"PHASE2":1234,"PHASE3":1236,"PHASE4":1238,"NA":1240},{"trials":1231,"activeCount":53},[],{"trials":1233,"activeCount":53},[],{"trials":1235,"activeCount":53},[],{"trials":1237,"activeCount":53},[],{"trials":1239,"activeCount":53},[],{"trials":1241,"activeCount":53},[1242],{"nctId":1243,"briefTitle":1244,"status":293,"phases":1245,"primaryCompletion":1246,"completion":1247,"start":1248,"enrollment":1249,"conditions":1250,"interventions":1254},"NCT03490149","Prediction of the Cognitive Effects of Electroconvulsive Therapy Via Machine Learning and Neuroimaging",[],"2021-12-01","2022-12-01","2018-01-02",180,[1251,18,1252,1253],"ECT","Cognitive Impairment","Memory Impairment",[1228],{"intervention":1256,"totalTrials":11,"cells":1257},"rising remifentanil concentrations",{"EARLY_PHASE1":1258,"PHASE1":1260,"PHASE2":1262,"PHASE3":1264,"PHASE4":1266,"NA":1268},{"trials":1259,"activeCount":53},[],{"trials":1261,"activeCount":53},[],{"trials":1263,"activeCount":53},[],{"trials":1265,"activeCount":53},[],{"trials":1267,"activeCount":53},[],{"trials":1269,"activeCount":53},[1270],{"nctId":1271,"briefTitle":1272,"status":134,"phases":1273,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":804,"conditions":1276,"interventions":1278},"NCT01234194","Composite Variability Index and Propofol Remifentanil Anesthesia",[47],"2010-07","2009-11",[1277],"Measure of Nociception",[1256,1279],"falling remifentanil concentrations",{"intervention":1279,"totalTrials":11,"cells":1281},{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1288,"PHASE4":1290,"NA":1292},{"trials":1283,"activeCount":53},[],{"trials":1285,"activeCount":53},[],{"trials":1287,"activeCount":53},[],{"trials":1289,"activeCount":53},[],{"trials":1291,"activeCount":53},[],{"trials":1293,"activeCount":53},[1294],{"nctId":1271,"briefTitle":1272,"status":134,"phases":1295,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":804,"conditions":1296,"interventions":1297},[47],[1277],[1256,1279]]